Please assess the completion status of the following clinical trial:

Trial Title: Gefitinib After Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed non-small cell lung cancer meeting 1 of the following stage criteria:~  * Stage IIIB~    * Pleural fluid and/or supraclavicular nodes allowed provided patient is not eligible for consolidation radiotherapy~ * Stage IV disease~* No disease progression after 2-6 courses of prior platinum-containing first-line palliative induction chemotherapy~* Brain metastases allowed provided patients are asymptomatic after cranial irradiation completed at least 4 weeks ago~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* WHO 0-2~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* Not specified~Renal~* Not specified~Pulmonary~* No history, signs, or symptoms of clinically active interstitial lung disease~  * Patients with chronic, stable, asymptomatic radiographic changes are eligible~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No psychological, familial, sociological, or geographical condition that would preclude study compliance and follow-up~* No other malignant disease within the past 5 years except basal cell skin cancer or adequately treated superficial carcinoma of the cervix~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No concurrent immunotherapy~Chemotherapy~* See Disease Characteristics~* Recovered from prior chemotherapy (alopecia allowed)~* No concurrent chemotherapy~Endocrine therapy~* Not specified~Radiotherapy~* See Disease Characteristics~Surgery~* Not specified~Other~* No prior epidermal growth factor receptor inhibitors~* No concurrent administration of any of the following drugs:~  * Phenytoin~ * Carbamazepine~ * Rifampin~ * Phenobarbital~ * Hypericum perforatum (St. John's wort)~* No other concurrent anticancer therapy~* No other concurrent experimental drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).